RET and lung carcinoma: Because no RET inhibitor has been indicated for the treatment of lung cancer in China yet, and the patient in our case had obtained PR to immunotherapy with a PFS of more than 5 months, so immunotherapy can still be a treatment option for patients with RET fusion lung cancer at present.